MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the MM and COVID-19 questionnaire.

Official Title
-----------------
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey

Conditions
-----------------
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Coronavirus

Intervention / Treatment
-----------------
* Behavioral: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma. Access to a computer or electronic device with internet access, or phone Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma Willing to give electronically-signed consent Ability to read questions in English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MGUS, SMM, MM Patients or their Caregivers<br>Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile. The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility. Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete. | Behavioral: Questionnaire<br>* Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID-19 Diagnosis and Treatment | Describe how patients diagnosed with COVID-19 were treated for the virus. | Up to one year | 
| Changes to Myeloma Treatment and Care | Describe which treatments were changed and how care was affected as a result of COVID-19 | Up to one year | 
| Health and Fitness | Describe how COVID-19 impacted patient's health and fitness | Up to one year | 
| Quality of Life (QOL) Distress Screening tool | Describe how patients rate their level of concern on psychosocial, practical, and physical needs during the COVID-19 pandemic using the Cancer Support Community's CancerSupportSource distress screening tool. | Up to one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Trial Familiarity | Describe how familiar patients are with multiple myeloma clinical trials. | Upon enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Questionnaire